On January 16, 2025, the Food and Drug Administration sanctioned the use of sotorasib (Lumakras, Amgen Inc.) in conjunction with panitumumab (Vectibix, Amgen Inc.) for adult patients diagnosed with KR...
On December 20, 2024, the Food and Drug Administration conferred accelerated approval for encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in conjunction with cetuximab and mF...
June 2024: The Food and Drug Administration has given accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) in combination with cetuximab for adults who have KRAS G12C-mutat...
The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic colorectal cancer (mCRC) who have undergone sp...
March 2023: In 2020, nearly 2 million cases of colorectal cancer will be diagnosed globally, making it the third most prevalent cancer type. It is the second leading cause of cancer-related deaths, a...
In February 2023, the Food and Drug Administration (FDA) sped up the approval of tucatinib (Tukysa, Seagen Inc.) and trastuzumab for the treatment of RAS wild-type HER2-positive colorectal cancer tha...
June 2022: A small study of rectal cancer patients yielded extraordinary results: 100 percent of the individuals were in remission. The results were published in The New England Journal of Medicine t...
May 2022: According to study findings published February 1 in the Journal of the National Cancer Institute, overweight or obese adults who lose more than 5 pounds over five years have a 46 percent lo...
July 6th 2021 : Colorectal cancer is the among most prevalent cause of cancer death in the the world. Regular screening, on the other hand, can detect colorectal cancer while it is tiny, hasn't sprea...
Gastrointestinal stromal tumor targeting drug Avapritinib (Avapriny, Ayvakit, BLU-285) is approved by USFDA on 9th January, 2020. The drug covers two indications: for the treatment of adult patients ...